Liver Diseases  >>  Peglamda (peginterferon lamda 1)  >>  Phase 1
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Peglamda (peginterferon lamda 1) / Nanogen Biopharma
NCT02063607: The Study of Safety, Pharmacokinetics, Pharmacodynamics of Peglamda (Peginterferon Lamda 1) on Healthy Volunteers and the Preliminary Evaluation of Peglamda and Hepasig (Ribavirin) Treatment's Effects on Chronic Hepatitis C Patients

Completed
1a/1b
60
RoW
Peginterferon lambda
Nanogen Pharmaceutical Biotechnology Joint Stock Company
Hepatitis C
02/15
07/16

Download Options